Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
暂无分享,去创建一个
S. Novello | R. Dziadziuszko | J. Wolf | J. Mazières | J. Wolf | A. Cardona | Å. Helland | H. Johannsdottir | A. Kotb | F. Griesinger | J. De Castro | J. Castro | B. Balas | I. Oh | M. Migliorino | A. Zeaiter | A. Kotb | A. Das-Gupta | J. de Castro | M. R. Migliorino
[1] G. Scagliotti,et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. , 2017, The Lancet. Oncology.
[2] Young Hak Kim,et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial , 2017, The Lancet.
[3] Rafal Dziadziuszko,et al. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[4] N. Yeh,et al. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Govindan,et al. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Socinski,et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. , 2016, The Lancet. Oncology.
[7] Nicholas G Zaorsky,et al. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. , 2015, The Lancet. Oncology.
[8] Lucio Crinò,et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Wakelee,et al. Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy , 2015, Current medical research and opinion.
[10] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[11] P. Jänne,et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] P. Iyengar,et al. Isolated central nervous system progression on Crizotinib , 2012, Cancer biology & therapy.